Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program

By sjmartinez • April 10, 2025

Horwitz ME, Schiller GJ, Tsai SB, Rezvani AR, Maziarz RT, Goshen U, Levy S, Schwarzbach A, Mazor RD, Stiff PJ. Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program. Transplant Cell Ther. 2025 Apr 7:S2666-6367(25)01138-8. doi: 10.1016/j.jtct.2025.04.005. Epub ahead of print. PMID: 40204073.

Tags: Hematology/Oncology, Publications

IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

Jiang H, Limsuwannarot S, Kulhanek KR, Pal A, Labiad O, Rysavy LW, Wong A, Su L, Cavender S, Soro J, Testa S, Ogana H, Waghray[...]

Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy

Hammer PM, Enamandram S, Ikeda DM, Lam MM, Wapnir IL, Chamberlain ED, Shaheen S, Caswell-Jin JL, Itakura H, Bean GR. Mammary small cell neuroendocrine carcinomas[...]

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis

Zaorsky NG, Sun Y, Nabid A, Zapatero A, Bolla M, Joseph D, Maingon P, Guerrero A, Gonzalez AA, San-Segundo CG, Cabeza Rodríguez MÁ, Sole JM,[...]